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A 41-year-old man, complaining of leg cramps, was found to have persistent hyperkalemia.
Except for mild hypertension, his physical examination and laboratory values to exclude
connective tissue diseases and diabetes mellitus were normal. Renal function testing revealed a
normal glomerular filtration rate and tubular capacity to acidify and dilute, as well as
near-normal ability to concentrate his urine. Hormonal evaluation revealed a normal cortisol,
as well as normal resting and stimulated renin and aldosterone levels. A selective defect in
tubular potassium secretion was demonstrated. In the absence of aldosterone deficiency or
renal dysfunction, it was assumed that the patient had primary renal resistance to aldosterone,
known aspseudohypoaldosteronism. Treatmentwith hydrochlorothiazide controlled his hyper-
kalemia and hypertension. His case emphasizes the diagnostic and therapeutic factors that
should be considered in evaluating and treating a non-hospitalized patient with sustained
hyperkalemia.
INTRODUCTION
A 41-year-old white man was referred to nephrology clinic for evaluation of
hyperkalemia, discovered in 1983 when serum potassium levels of5.5 and 5.4 mEq/l
were noted during anevaluation forintermittent muscle ache. Hisonlyothermedical
problemwas mild hypertension, controlledwith clonidine. He took no othermedica-
tions, and his only complaint was of leg cramps after heavy exertion, which had
started one yearpreviously. His family history was significant for a son and daughter
with confirmed hyperkalemia, and a sister reported to have "high potassium." There
was no family history of paralysis or muscle weakness. His physical exam was
completely normal, including a blood pressure (BP) of 130/82. An intravenous
pyelogram was normal, with no evidence ofobstruction or urinary reflux. Evaluation
for connective tissue diseases, systemic lupus erythematosus (SLE), and neurologic
diseases, with serologies and an electromyogram (EMG), was negative. Pertinent lab
values are presented in Table 1.
Historical chemistry values demonstrated chronic hyperkalemia with normal
serum bicarbonate values and normal serum creatinine concentration. White blood
cell and platelet counts were normal, and plasma potassium measurements con-
firmed hyperkalemia. As shown in Table 1, his glomerular filtration rate, as reflected
by his serum creatinine level, and his renal tubular ability to lower urine pH and
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TABLE 1
Patient Laboratory Values
Test
Plasma K+
Serum Na+
Cl-
HCO-
BUN
Creatinine
Urine Studies pHa
pH after acid loadb
U/A
UOsm maxc
UOsmmin'
1TFKGe
Adrenal Studies Cortisol (random)
Renin
Aldosterone
Baseline
2.9
16
5.2-6.8 mEq/l
142-145 mEq/l
106-111 mEq/l
23-26 mEq/l
13-15 mg/dl
1.0 mg/dl
5.0-5.5
4.8
Negative for glucose, ketones, and protein
626 mosm (normal > 800 mosm/l)
60 mosm (normal < 100 mosm/l)
2.6-2.8
18 p.g/dl
Stimulated
7.8 ng/ml/hour
50 ng/dl
apH from early morning sample
bCollected after ammonium chloride load
'Collected during overnight water deprivation study
dCollected during water loading study
'Calculated as Uk/Pk . UP,mPos; Normalvalue, 8.7 + 2.7
dilute urine were normal. His urine osmolarity after an overnight water deprivation
study was less than expected (626 versus 800 mosm/l), but the study was unsuper-
vised, and it is possible that the patient was not stimulated maximally to conserve
water. The patient's laboratory values also revealed normal renin activity and
aldosterone concentration under baseline and stimulated conditions; however, his
transtubular potassium gradient (TTKG), calculated by dividing the ratio ofurine to
serum potassium by the ratio of urine to plasma osmolality (Uk/Sk UosmlSosm) was
low (2.7). This test reflects the level ofmineralocorticoid activity on the distal tubule
to stimulate potassium secretion [1,2]. An average value for the TTKG is 8.7 + 2.7 in
normal patients, rising to 13.1 + 3.8 after an acute potassium load [3]. In the absence
of mineralocorticoid activity, the TTKG is close to 3 [2]. The low TTKG in this
patient with normal aldosterone levels suggests a defect in renal distal tubular
responsiveness to aldosterone.
The patient was switched from clonidine to hydrochlorothiazide, which controlled
both his hyperkalemia and his hypertension. When seen in follow-up, he has
remained normotensive, with serum potassium levels between 4.0-4.5 mEq/l.
DISCUSSION
This patient illustrates several interesting features in the evaluation ofhyperkale-
mia. Among the most common causes of hyperkalemia, listed in Table 2, are
medications and renal failure, both absent in our patient. Of the remaining causes,
most occur acutely (trauma, acidosis, intravascular hemolysis) or are related to in
vitro release ofpotassium (hemolysis in vitro, thrombocytosis, leukocytosis). Regard-
ing causes for chronic hyperkalemia, our patient had no signs or symptoms suggest-
ing diseases such as periodic paralysis, systemic lupus erythematosus (SLE),
Result
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TABLE 2
Common Causes ofHyperkalemia
1. Factitious
Laboratory error
Pseudohyperkalemia: in vitro hemolysis, thrombocytosis, leukocytosis
2. Increased input
Exogenous: salt substitutes, medications, diet
Endogenous: hemolysis, muscle trauma, gastrointestinal bleeding
3. Decreased output
Renal failure: GFR < 15 to 20 ml/minute
Inadequate delivery ofsodium and water to the distal tubule
Impaired renin-aldosterone axis:
Endocrinologic: Addison's disease, primary hypoaldosteronism, angiotensin
deficiency or insensitivity
Medications: heparin, beta-adrenergic blockers, prostaglandin inhibitors
(NSAIDs), ACE inhibitors
Renal tubular defects: sickle-cell disease, SLE, post-obstructive nephropa-
thy, familial, post-renal transplant, amyloidosis, pseudohypoaldoster-
onism
Inhibition oftubular secretion: spironolactone, triamterene, amiloride, digi-
talis
4. Abnormal potassium distribution
Acidosis
Hypertonicity (hyperglycemia)
Hormonal deficiencies: insulin, aldosterone, epinephrine
Miscellaneous: exercise, arginine hydrochloride infusion, periodic paralysis
Abbreviations: ACE inhibitors-angiotensin converting enzyme inhibitors; GFR-glomerular filtration
rate; NDSAIDs-non-steroidal anti-inflammatory drugs; SLE-systemic lupus erythematosus
amyloidosis, or ureteral obstruction. Furthermore, he had none of the laboratory
features of Addison's disease, chronic metabolic acidosis, or diabetes mellitus.
Errors in measurement were eliminated through measuring plasma K+ and measur-
ingwhite blood cell and platelet counts.
To exclude selective hypoaldosteronism, another relatively common cause of
chronic hyperkalemia, it is necessary to demonstrate normal adrenal responsiveness
to maneuvers which stimulate aldosterone production, such as ACTH infusion,
upright posture, volume contraction, andpotassium infusion. Ourpatient responded
normallytouprightposture andvolume contractionbyincreasinghis serumaldoster-
one (Table 1). This ability to augment his aldosterone production when stimulated,
coupledwith alackofevidence foranyoftheothercausesforhyperkalemia, suggests
that his defect is resistance to the action of aldosterone, either a selective tubular
defect or a moregeneralized cellular defect in potassium uptake. Theformer clinical
entity has been called pseudohypoaldosteronism [4,5], and the next part of this
discussion will deal with its clinical manifestations.
The early descriptions of pseudohypoaldosteronism were in infants [6,7], charac-
terized byfailure to thrive, metabolic acidosis, hyperkalemia, and mineralocorticoid-
resistant urinary sodium wasting. Plasma renin and aldosterone were both elevated,
and there were no other adrenal enzyme abnormalities. The congenital defect is
related to a lack or deficiency ofaldosterone receptors in some cases [8,9] and canbe
inherited [10-13]. In addition, children have been reported with abnormally high
urinary excretion ofthe prostaglandins PGE2 and PGF2a [14], which may be second-
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aryto the basicdefect in pseudohypoaldosteronism. Childrenwithpseudohypoaldos-
teronism respond normally to infusion of ACTH or potassium with increases in
urinary and serum aldosterone [12], suggesting an intact normal adrenal responsive-
ness. The children usually respond to large amounts of dietary sodium chloride
replacement with resumption of normal growth and often eventually recover normal
renal handling ofsodium and potassium. This group has been classified as pseudohy-
poaldosteronism type I by Schambelan et al. [5]. It is the most common form of
pseudohypoaldosteronism, as judged by the number of cases reported in the litera-
ture [8,9,12,14-21].
More recently, a group of adult patients has been described with features similar
to those of the children described above [4,5,13,22-29]. These patients also have a
combination of hyperkalemia and metabolic acidosis. Their renin-angiotensin-
aldosterone responds normally to maneuvers such as volume contraction or ACTH
infusion. The clinical feature that serves to distinguish them from the children above
is their lack of salt wasting [5]. Most ofthese patients, in fact, are hypertensive. The
patients vary in their response to the diagnostic and therapeutic interventions, but
with one exception [23] all of the published cases have demonstrated metabolic
acidosis. This acidosis is a type IV renal tubular acidosis, related to impaired renal
ammonia generation. (It is interesting to note that our patient exhibited no acidosis
in five years oflaboratory testing.) Characteristically their hypertension is described
as severe, with systolic blood pressures between 190 and 210mm Hg, and their serum
potassium ranges between 5.3 mEq/l and 8.2 mEq/l. This group of patients is now
classified as pseudohypoaldosteronism type II. In distinction to the children de-
scribed above, there is little long-term follow-up available for these patients, and
whether they regain normal renal handling ofpotassium with time is not known.
In order to diagnose pseudohypoaldosteronism, it is important first to exclude the
more common causes of hyperkalemia listed in Table 2. The next step is to verify
normal aldosterone secretion in response to renin stimulation. The third step in the
diagnosis is to verify renal resistance to the effects ofmineralocorticoids through the
administration offludrocortisone ordeoxycorticosterone (DOCA) for severalweeks.
The patient with pseudohypoaldosteronism will demonstrate sustained hyperkale-
mia resistant to the kaliuretic effects of mineralocorticoids. This test must be
carefully supervised, since mineralocorticoids canworsen congestive heart failure by
stimulating salt and water retention. Figure 1 shows the course of a typical patient
with pseudohypoaldosteronism typeII during treatment with oral mineralocorticoid
therapy [5]. Urinary and serum potassium remain unchanged, despite increased
urinary sodium reabsorption immediately after starting fludrocortisone and again
after the addition ofDOCA. An important note is that large doses offludrocortisone
(0.5-1.0 mg per day) must be used to document resistance to mineralocorticoid
action. It is also important that the patient's intake of potassium remain constant
during the test period.
Finally, the patient with pseudohypoaldosteronism type I is distinguished from
one with typeII by putting the patient on a sodium-restricted diet. Normal ability to
conserve sodium (urinary sodium <10 mEq/l) will classify the patient as having
pseudohypoaldosteronism typeII [5].
It has been proposed that the defect in pseudohypoaldosteronism type II is
increased chloride reabsorption in the distal tubule [4,5,30]. This "chloride shunt"
could impair potassium secretion by making the potential difference in the distal
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FIG. 1. Effect of fludrocorti-
sone therapy, with and without
DOCA, on serum potassium
and urinary excretion of potas-
sium (UkV) sodium (UN9V), and
chloride (Uc,V) in a typical pa-
tient with pseudohypoaldoste-
ronism. Both mineralocorti-
coids caused sodium retention
without increasing potassium
46 48 excretion orlowering serumpo-
tassium levels. Reprinted with
permission [5].
tubule less negative, decreasing one of the major driving forces for potassium
secretion. Evidence for this hypothesis comes from studies comparing the response
to sodium chloride versus sodium sulfate infusion in patients with pseudohypoaldo-
steronism type II. Figure 2 shows the result of infusion of sodium chloride or sodium
sulfate in two such patients, demonstrating their failure to increase potassium
excretion during sodium chloride infusion compared with normal controls. In
contrast, infusion with sodium sulfate increased urinary potassium excretion in both
the patient and the controls. Sulfate and bicarbonate are anions that normally
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FIG. 2. Effect of sodium chloride (left panel) and sodium sulfate (right panel)
infusion on fractional potassium clearance (Ck/GFR 100) in a single patient with
pseudohypoaldosteronism (closed circles) and in two control patients (open circles
and triangles). Potassium excretion increased with both maneuvers in controls,
whereas the patient with pseudohypoaldosteronism was resistant to the kaliuretic
effect ofNaCl due to "chloride shunting." Reprintedwith permission [5].
augment potassium excretion, perhaps by making the potential difference more
negative in the lumen of the distal tubule. Patients with pseudohypoaldosteronism
will increase their potassium excretion during an infusion ofeither sodium sulfate or
sodium bicarbonate, although some patients will have a lower potassium excretion
than controls [22,30]. In contrast, sodium chloride, which normally increases potas-
sium secretion by increasing solute delivery to the distal tubule, fails to increase
potassium secretion in these patients, since the "chloride shunt" prevents any
change in the potential difference in the distal tubule. More patientswithpseudohy-
poaldosteronism type II need to be evaluated in this manner to determine whether a
"chloride shunt" really is the mechanism in this disorder.
Although our patient was not tested with mineralocorticoids to document resis-
tance to their effects, his impaired potassium secretion and lowTFKG, in the setting
of a normal serum aldosterone level, suggest pseudohypoaldosteronism. Further-
more, his clinical course is consistent with pseudohyopoaldosteronism type II, given
his absence of clinical signs of salt wasting. In fact, his hypertension responded to
diuretic therapy, suggesting sodium retention as part ofits mechanism.
Treatment ofpseudohypoaldosteronism depends on the severity ofthe hyperkale-
mia, aswell as other associated medical problems such as acidosis and hypertension.
For most patients, use of a low-potassium diet coupled with a mild diuretic should
control their hypertension and correct their hyperkalemia. Our observation is that
thiazide diuretics are very effective in increasing potassium excretion, perhaps
through their ability to increase sodium delivery to the distal tubule, allowing forPSEUDOHYPOALDOSTERONISM 253
maximalpotassium excretion. Thiseffectivenessofthiazide diuretics inpseudohypoal-
dosteronism has been observed by others [23,29]. Patients should be warned not to
allow themselves to become volume-contracted, as this condition will worsen potas-
sium excretion by diminishing delivery of filtrate into the distal tubule, upon which
potassium secretion depends. Ifthese measures fail, sodiumbicarbonate canbe used
orally to attempt to increase potassium excretion. Ion exchange resins (kayexalate)
are a last step in the control ofchronic, life-threatening hyperkalemia. Since starting
hydrochlorothiazide, our patient has had no recurrence ofhis hyperkalemia, and his
hypertension has beenwell controlled.
Chronic hyperkalemia poses a diagnostic and therapeutic challenge for the
physician. After exclusion of the more common causes, a group of patients can be
found whose hyperkalemia results from pseudohypoaldosteronism, a defect in renal
excretion ofpotassium despite normal aldosterone production. Recognition ofthese
patients is important therapeutically, since they fail to respond to exogenous
mineralocorticoids, and treatment with thiazide diuretics often corrects their hyper-
kalemia and hypertension. In addition, family members should be screened for
asymptomatic hyperkalemia. As more patients such as the one described in this
paper are identified, their long-term clinical course, as well as the nature of their
renal tubular defect, will become elucidated.
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